Exchange: NASDAQ·Updated 07:30 PM EDT
INBX logo

INBX Inhibrx Inc

$95.01
$2.25
(2.43%)
Today
Closed $95.01
$0.00
(0.00%)
After Hours
EarningsNov 13
Mkt Cap$1.37B
Vol86,819.00

About INBX

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
33

Bearish Sentiment

How do you feel about INBX?

CH_Expat
$INBX $KOD As mentioned: IQ 75 Cubie logic is: Data good good, stock price boom boom. Too dumb to understand how important it is to have a watchlist, wait for corrections and buy derisked quality bios at a discount. But when you are dumb, you quote postings from three months instead of looking at my two actual holdings - which is fine for me as I am not invested. As mentioned, dumb as heck.
1
2
Terzman
$INBX lets repeat an obvious … no raise on landscape… loan facility in hand .. insiders bought here in size.. = message to shorts = gfys
3
CH_Expat
$INBX Interesting. I am considering a position here and I always value your opinion. What makes you bearish?
2
chefboobyflay
$INBX Shorts just gonna take this for a ride back to $80 with no near term catalysts in sight.. I don’t see a takeout happening soon either. I’ll be buying but disappointed this hasn’t re-rated to the analyst price targets zone.
1
CH_Expat
$INBX Why so little cash? Unusual for quality bio. I would be interested, but this is strange. If someone can explain it to me: Thanks.
MBWallingford
$INBX another flop read out. This one was worse at it really did not go up to the previous highs. Ok. They bought a tiny bit of shares? Small positive. Expanded scope -how will they pay? -dilution certainly coming. -delay monetization -no guarantee of accelerated approval -positive interim results. But they are not final. -pricing shows investors are not impressed. -very little volume. Why am I in this stock?

Advertisement|Remove ads.